drugset / Trial / NCT06366243

A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult Participants

NCT06366243

Phase 1 Completed 20 enrolled Cerevel Therapeutics, LLC
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to evaluate the potential of gastric pH-dependent drug-drug interaction effect of esomeprazole, a proton pump inhibitor (PPI), on the pharmacokinetics (PK) of emraclidine in healthy adult participants.

Timeline

Start
2024-05-10
Primary completion
2024-06-20
Completion
2024-06-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Emraclidine Small molecule 30 mg Oral
Subject Esomeprazole Small molecule 40 mg Oral

Indications

No indication recorded.